9-(((S)-1-((2S,4R)-4-羥基-2-((4-(4-甲基噻唑-5-基)芐基)氨基甲?；?吡咯烷-1-基)-3,3-二甲基-1-氧代丁烷-2-基)氨基)-9-氧代壬酸
| 中文名稱(chēng) | 9-(((S)-1-((2S,4R)-4-羥基-2-((4-(4-甲基噻唑-5-基)芐基)氨基甲?；?吡咯烷-1-基)-3,3-二甲基-1-氧代丁烷-2-基)氨基)-9-氧代壬酸 |
|---|---|
| 中文同義詞 | 9-(((S)-1-((2S,4R)-4-羥基-2-((4-(4-甲基噻唑-5-基)芐基)氨基甲酰基)吡咯烷-1-基)-3,3-二甲基-1-氧代丁烷-2-基)氨基)-9-氧代壬酸;(S,R,S)-AHPC-AMIDO-C7-ACID;VH032-庚酸;化合物 VH 032 AMIDE-ALKYLC7-ACID;9-[[(S)-1-[(2S,4R)-4-羥基-2-[[4-(4-甲基-5-噻唑基)芐基]氨基甲?；鵠-1-吡咯烷基]-3,3-二甲基-1-氧代-2-丁基]氨基]-9-氧代丙酸 |
| 英文名稱(chēng) | L-Prolinamide, N-(8-carboxy-1-oxooctyl)-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)- |
| 英文同義詞 | L-Prolinamide, N-(8-carboxy-1-oxooctyl)-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)-;9-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-9-oxononanoic acid;VH 032 amide-alkylC7-acid;VH032-C6-COOH;8-{[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}octanoic acid;9-[[(S)-1-[(2S,4R)-4-Hydroxy-2-[[4-(4-methyl-5-thiazolyl)benzyl]carbamoyl]-1-pyrrolidinyl]-3,3-dimethyl-1-oxo-2-butyl]amino]-9-oxononanoic Acid |
| CAS號(hào) | 2172819-76-8 |
| 分子式 | C31H44N4O6S |
| 分子量 | 600.77 |
| EINECS號(hào) | |
| 相關(guān)類(lèi)別 | |
| Mol文件 | 2172819-76-8.mol |
| 結(jié)構(gòu)式 |  |
9-(((S)-1-((2S,4R)-4-羥基-2-((4-(4-甲基噻唑-5-基)芐基)氨基甲?；?吡咯烷-1-基)-3,3-二甲基-1-氧代丁烷-2-基)氨基)-9-氧代壬酸 性質(zhì)
| 沸點(diǎn) | 888.3±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.229±0.06 g/cm3(Predicted) |
| 溶解度 | DMSO: Soluble: =10 mg/ml Ethanol: Sparingly soluble: 1-10 mg/mlPBS (pH 7.2): Slightly soluble: 0.1-1 mg/ml |
| 形態(tài) | 固體 |
| 酸度系數(shù)(pKa) | 4.77±0.10(Predicted) |
| 顏色 | 白色至米白色 |
9-(((S)-1-((2S,4R)-4-羥基-2-((4-(4-甲基噻唑-5-基)芐基)氨基甲?；?吡咯烷-1-基)-3,3-二甲基-1-氧代丁烷-2-基)氨基)-9-氧代壬酸已被用于合成靶向癌細(xì)胞間變性淋巴瘤激酶 (ALK) 的 PROTAC。